Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037183 | 0.78 | TUBB1 (0.42) | TUBB1ACHEFDPSALOX5PTGS1 | |
| SCHEMBL13614803 | 0.77 | TP53 (0.45) | TUBB1NFE2L2HDAC1HDAC6ACHE | |
| SCHEMBL16961237 | 0.77 | TUBB1 (0.42) | TUBB1NFE2L2HDAC1HDAC6ACHE | |
| SCHEMBL229897 | 0.77 | ALDH1A1 (0.47) | TUBB1NFE2L2HDAC1HDAC6GPR183 | |
| SCHEMBL29453098 | 0.77 | ALDH1A1 (0.47) | TUBB1NFE2L2HDAC1HDAC6GPR183 | |
| SCHEMBL12506745 | 0.76 | TUBB1 (0.49) | TUBB1NFE2L2HDAC1HDAC6ACHE | |
| SCHEMBL10624527 | 0.76 | TUBB1 (0.49) | TUBB1NFE2L2HDAC1HDAC6ACHE | |
| SCHEMBL14569993 | 0.74 | NFE2L2 (0.74) | TUBB1NFE2L2ALOX5PTGS1PTGS2 | |
| SCHEMBL13463210 | 0.74 | NFE2L2 (0.74) | TUBB1NFE2L2ALOX5PTGS1PTGS2 | |
| SCHEMBL7087802 | 0.73 | CYP3A4 (0.46) | FDPSALOX5PTGS1PTGS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20030232996-A1 | Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes | PHARMACIA CORPORATION | 2003-12-18 | — | — | US | disclosed |
| US-6600052-B1 | With a ring cyclizing reagent to form the compound of Formula V to yield a compound of Formula V: inhibitors of the cyclooxygenase- II enzyme. and antiinflammatory agents and analgesic pharmaceutical agents. | PHARMACIA CORPORATION | 2003-07-29 | — | — | US | disclosed |
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1276736-A2 | REGIOSELECTIVE SYNTHESIS OF 3,4-DI(CARBOCYCLYL OR HETEROCYCLYL)THIOPHENES | Pharmacia Corporation (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2001081333-A2 | REGIOSELECTIVE SYNTHESIS OF 3,4-DI(CARBOCYCLYL OR HETEROCYCLYL)THIOPHENES | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| US-3932498-A | ANTIINFLAMMATORY, ANTIPYRETICS, ANALGESICS | MERCK & CO., INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | TUBB1 455/4885NFE2L2 46/4885HDAC1 718/4885 |
| US-20030232996-A1 | Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes | CCNE2, CCNC, CYP3A4 | TUBB1 1366/4885NFE2L2 1258/4885HDAC1 1259/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | TUBB1 443/4885NFE2L2 45/4885HDAC1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.